What does the research say about CA19-9/FUT2/3 panel?

CA19-9/FUT2/3 panel

There is 1 paper on CA19-9/FUT2/3 panel in aging research: 1 observational study in people. The newest story, Nov 9, 2026: “Blood test panel better distinguished pancreatic cancer cases”.

Biomarker

1 paper studies it1 finding

See all 1 papers on CA19-9/FUT2/3 panel

“Two panels had significantly higher AUCs than serum CA19-9 alone, the CA19-9/FUT2/3 panel (AUC = 96.3, P = 0.002)”

Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery StudyClinical cancer research : an official journal of the American Association for Cancer Research2026doi:10.1158/1078-0432.ccr-25-4061

Humans1

Associations

Pancreatic ductal adenocarcinoma

upin humans1

1 study

CA19-9/FUT2/3 panel predicts pancreatic ductal adenocarcinoma in humans (PDAC vs controls) (AUC = 96.3, P = 0.002).
“Two panels had significantly higher AUCs than serum CA19-9 alone, the CA19-9/FUT2/3 panel (AUC = 96.3, P = 0.002)”
HumansPDAC vs controls
Blood test panel better distinguished pancreatic cancer cases
Clinical cancer research : an official journal of the American Association for Cancer ResearchMar 23, 2026

More on Pancreatic ductal adenocarcinoma

Latest

1 paper in 12 months

Clinical Cancer ResearchMar 23

Blood test panel better distinguished pancreatic cancer cases

The leading panel scored 96.3 versus 91.7 for a single blood marker on a measure of how well tests separated cancer cases from controls.The leading panel scored 96.3 versus 91.7 for a single blood marker on a measure of how well tests separated cancer cases from controls.

Case-control · 280 peoplePancreatic ductal adenocarcinoma

Paper

CA19-9/FUT2/3 panel

Associations

Latest

Blood test panel better distinguished pancreatic cancer cases

Related